Professor Erik Stroes, Amsterdam University Medical Center, Amsterdam, The Netherlands, summarises clinical trial evidence on apoC3 or ANGPTL3 inhibition, and considers the potential of combining apoC3, ANGPTL3 and/or PCSK9 targeting agents.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
